## TRICARE Prior Authorization Request Form for **futibatinib** (Lytgobi)



## JOHNS HOPKINS HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

## **USFHP Pharmacy Prior Authorization Form**

To be completed by Requesting provider		
Drug Name:	Strength:	
Dosage/Frequency (SIG):	Duration of Therapy:	

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step	Please complete patient and physician information (please print):				
1	Patient	t Name:	Physician Name:		
	Spons				
		Date of Birth: Secure Fax #:			
Step	Please complete the clinical assessment:				
2	1.	Is the patient GREATER THAN or EQUAL to 18 year	years	☐ Yes	□ No
	of age?			Proceed to question 2	STOP
					Coverage not approved
	Is the requested medication being prescribed by or in consultation with a hematologist or oncologist?			☐ Yes	□ No
		consultation with a hematologist of officologist	f	Proceed to question 3	STOP
					Coverage not approved
	Has the patient previously been treated for unresectable locally advanced or metastatic cholangiocarcan with a fibroblast growth factor		☐ Yes	□ No	
			Proceed to question 6	Proceed to question 4	
	receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test?		ent as		
	4.	What is the diagnosis or indication?			
			Proceed to question 5		
	5. Is the diagnosis cited in the National Comprehensiv Cancer Network (NCCN) guidelines as a category 1 2A, or 2B recommendation?		□ Yes	□ No	
		гу 1,	Proceed to question 6	STOP	
	•				Coverage not approved
-	6. Will the patient be monitored for retinal pigment epithelial detachment, hyperphosphatemia, and tissue mineralization?		□ Yes	□ No	
				Proceed to question 7	STOP
					Coverage not approved

## TRICARE Prior Authorization Request Form for **futibatinib** (Lytgobi)

	7.	Is the patient of childbearing potential?	☐ Yes	□ No
			Proceed to question 8	Sign and date below
	8.	What is the patient's gender?	□ Female	□ ale
			Proceed to question 9	Proceed to question 12
	9.	Is the patient pregnant?	☐ Yes	□ No
			STOP	Proceed to question 10
			Coverage not approved	
	10. Has it been confirmed that the patient is not pregnant	☐ Yes	□ No	
		by negative HCG (human chorionic gonadotropin)?	Proceed to question 11	STOP
				Coverage not approved
	11.	. Will the patient avoid breastfeeding during treatment and for at least 1 week after the cessation of treatment?	☐ Yes	□ No
			Proceed to question 12	STOP
	a saunone.		Coverage not approved	
	12. Does the patient agree to use effective contraception during treatment and for at least 1 week after cessation of therapy?	☐ Yes	□ No	
		during treatment and for at least 1 week after cessation of therapy?	Sign and date below	STOP
		•		Coverage not approved
Step	I certif	fy the above is true to the best of my knowledg	<b>je.</b> Please sign and d	ate:
3				
	-	Prescriber Signature	Date	<del>.</del>
				[17 May 2023]

For Internal Use Only				
Approved:	Duration of Approval:month(s)			
Denied:	Authorized By:			
☐ Incomplete/Other:	PA#:			
Date Faxed to MD:	Date Decision Rendered:			